Drugs / GQ1005
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06154343 | Nov 2022 → Dec 2024 | carcinoma | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07673029 | Jan 2025 → Jan 2027 expected | HER2 positive breast carcinoma | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GQ1005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06154343 ↗ |
| Modality | Other / unclassified | “an antibody drug conjugate” NCT06154343 ↗ |
| Route | Intravenous | “GQ1005 will be administered intravenously every 21 days.” NCT06154343 ↗ |